Biohaven (BHVN) Stock Forecast & Price Target

$46.65

-1.34 (-2.79%)

(As of 10/3/2024 ET)

Biohaven - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 14 Analyst Ratings

Sell
0

Hold
0

Buy
14

Based on 14 Wall Street analysts who have issued ratings for Biohaven in the last 12 months, the stock has a consensus rating of "Buy." Out of the 14 analysts, 13 have given a buy rating, and 1 has given a strong buy rating for BHVN.

Consensus Price Target

$61.92
32.73% Upside

According to the 14 analysts' twelve-month price targets for Biohaven, the average price target is $61.92. The highest price target for BHVN is $76.00, while the lowest price target for BHVN is $54.00. The average price target represents a forecasted upside of 32.73% from the current price of $46.65.

Get the Latest News and Ratings for BHVN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biohaven and its competitors.

BHVN Analyst Ratings Over Time

Type	Current Forecast 10/5/23 to 10/4/24	1 Month Ago 9/5/23 to 9/4/24	3 Months Ago 7/7/23 to 7/6/24	1 Year Ago 10/5/22 to 10/5/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	10 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$61.92	$54.44	$54.71	$25.25
Forecasted Upside	32.73% Upside	43.80% Upside	60.59% Upside	4.55% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Next opportunity for crypto millions (Ad)

October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…

Go here to discover the coin that could define this historic bull run with gains kicking off this mo

BHVN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BHVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biohaven Stock vs. The Competition

Type	Biohaven	Medical Companies	S&P 500
Consensus Rating Score	3.07	2.78	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	31.63% Upside	849.81% Upside	7.89% Upside
News Sentiment Rating	Neutral News See Recent BHVN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/3/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$55.00 ➝ $68.00	+43.49%
9/24/2024	Bank of America 4 of 5 stars		Boost Target	Buy ➝ Buy	$52.00 ➝ $62.00	+39.70%
9/24/2024	Sanford C. Bernstein 3 of 5 stars	W. Pickering Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$55.00 ➝ $66.00	+48.72%
9/24/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
9/24/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$59.00 ➝ $68.00	+48.05%
9/24/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$59.00 ➝ $59.00	+28.46%
Get the Latest News and Ratings for BHVN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.
9/23/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$55.00 ➝ $60.00	+30.63%
9/23/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$58.00 ➝ $60.00	+32.28%
9/23/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$66.00 ➝ $76.00	+67.55%
9/16/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$57.00	+49.68%
8/30/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Schram Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/13/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$55.00 ➝ $54.00	+47.46%
7/24/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$58.00	+53.40%
3/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$35.00 ➝ $55.00	+14.25%
6/5/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$24.00 ➝ $28.00	+29.33%
1/24/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$24.00	+25.00%
11/7/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set Target		$25.00	+61.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:34 AM ET.

BHVN Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Biohaven is $61.92, with a high forecast of $76.00 and a low forecast of $54.00.
: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last twelve months. There are currently 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BHVN shares.
: According to analysts, Biohaven's stock has a predicted upside of 32.73% based on their 12-month stock forecasts.
: Over the previous 90 days, Biohaven's stock had 1 upgrade by analysts.
: Biohaven has been rated by research analysts at Bank of America, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, UBS Group, and William Blair in the past 90 days.
: Analysts like Biohaven more than other "medical" companies. The consensus rating for Biohaven is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BHVN compares to other companies.